Yao Ming Kangde's decline extended to 2%, and the stock price hit a new low since August 2019. The CRO concept generally declined, with Jiuzhou Pharmaceutical falling more than 8%, and Gloria & Sannuo Biotech falling more than 3%.
药明康德跌幅扩大至2%，股价创2019年8月以来新低。CRO概念普遍下挫，九洲药业跌超8%，凯莱英、三诺生物跌逾3%。
Yao Ming Kangde's decline extended to 2%, and the stock price hit a new low since August 2019. The CRO concept generally declined, with Jiuzhou Pharmaceutical falling more than 8%, and Gloria & Sannuo Biotech falling more than 3%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.